Welcome to our dedicated page for Personalis news (Ticker: PSNL), a resource for investors and traders seeking the latest updates and insights on Personalis stock.
Personalis, Inc. (symbol: PSNL) is a leading genome-scale diagnostics company dedicated to advancing the field of genome-guided medicine. The company's mission is to extract the most accurate genetic data from each sample and draw reliable, medically-focused conclusions. Personalis leverages cutting-edge whole genome and exome sequencing techniques, conducted in their state-of-the-art laboratory, to provide comprehensive insights.
Personalis offers a range of products and services designed to support academic, pharmaceutical, and biotech researchers. Their flagship products include ImmunoID NeXT, NeXT Personal, and NeXT Dx Test, which cater to diverse needs including personalized cancer vaccines and next-generation cancer immunotherapies. Additionally, their solutions serve those engaged in large case-control and family-based genome studies of complex or Mendelian diseases, pharmacogenomics, and cancer research.
Their proprietary databases, advanced human reference sequences, and sophisticated algorithms ensure accurate and comprehensive end-to-end human genome sequencing and analysis. Personalis' commitment to quality and innovation positions them as a critical player in the evolving landscape of genomic medicine.
Recent achievements include partnerships with key pharmaceutical companies to enhance the development of personalized cancer treatments. The company continues to innovate and expand its service offerings, ensuring researchers and clinicians have access to the most advanced tools for genomic analysis.
For those seeking the latest updates and relevant information on Personalis, Inc., StockTitan provides a comprehensive list of news and developments, ensuring investors and stakeholders stay informed on this pioneering company's performance and advancements.
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced cancer genomics, will present at the 2021 Bank of America Healthcare Conference on May 13, 2021, at 5:00 p.m. Eastern Time. Renowned for its population sequencing and cancer genomics innovations, Personalis operates one of the largest sequencing programs globally, serving the U.S. Department of Veterans Affairs Million Veterans Program. Their ImmunoID NeXT Platform provides comprehensive molecular data on cancer and immune responses, enhancing next-generation therapy development.
Personalis, Inc. (Nasdaq: PSNL) will announce its Q1 2021 financial results on May 5, 2021, after market close. The company will host a conference call and webcast at 2:00 p.m. PT / 5:00 p.m. ET to discuss these results and provide recent highlights. Interested participants can join the live call via phone or through the company's website. Personalis specializes in advanced genomics for cancer, serving as a key sequencing provider for major initiatives like the U.S. Department of Veterans Affairs Million Veterans Program.
Personalis, Inc. (Nasdaq: PSNL) announced its participation in the American Association for Cancer Research (AACR) Annual Meeting 2021, scheduled for April 10-15 and May 17-21, 2021.
The company will present new scientific data related to its ImmunoID NeXT platform, which enables comprehensive analysis of tumors and their immune microenvironments. Key presentations will cover topics such as HLA loss of heterozygosity, therapeutic resistance mechanisms in head and neck cancer, and antigen processing.
Personalis, Inc. (Nasdaq: PSNL) announced a collaboration with MapKure, LLC to use the Personalis NeXT Platform™ in clinical trials for BGB-3245, a next-generation B-RAF inhibitor targeting advanced solid tumors. This partnership aims to utilize the NeXT Platform for broad tumor immunogenomic profiling, facilitating the understanding of relevant biomarkers for BGB-3245. The collaboration emphasizes advanced biomarker development for improved cancer treatment. Financial details were not disclosed.
Personalis, Inc. (Nasdaq: PSNL) has appointed Dr. Woody Myers to its Board of Directors, enhancing its leadership with his extensive healthcare experience. Dr. Myers, previously with Blue Cross & Blue Shield of Arizona, has served on various boards and has a strong background in medicine and health policy. His addition is seen as a strategic move to bolster Personalis' commitment to precision medicine. Former director Patrick J. Balthrop has resigned, effective March 8, 2021. CEO John West expressed enthusiasm about Dr. Myers’ potential contributions to the company's vision.
Personalis, Inc. (Nasdaq: PSNL) reported record revenue of $20.2 million for Q4 2020, an 11% increase from Q4 2019. The company achieved a total of 45 customers for NeXT services and completed over 100,000 whole genomes under the VA MVP contract. Despite revenue growth, the net loss increased to $13.3 million from $6.6 million a year prior. The gross margin for Q4 was 30.1%, down from 36.2% in Q4 2019. For Q1 2021, revenues are expected around $20.3 million, with a projected net loss between $14.0 million and $15.0 million.
Personalis (Nasdaq: PSNL) and Natera (Nasdaq: NTRA) have launched a partnership to advance personalized oncology. Their collaboration combines Personalis’ NeXT tumor profiling with Natera’s Signatera ctDNA platform for monitoring treatment and assessing molecular residual disease. Natera will validate Signatera assays using Personalis' data and handle commercialization. This non-exclusive agreement aims to enhance the integration of these technologies in clinical and research applications, expanding patient access to innovative cancer monitoring solutions.
Natera, Inc. (Nasdaq: NTRA) and Personalis, Inc. (Nasdaq: PSNL) have announced a partnership aimed at enhancing personalized oncology. This non-exclusive agreement integrates Personalis' NeXT tumor profiling products with Natera's Signatera ctDNA platform for monitoring treatment and assessing molecular residual disease (MRD). Natera will validate Signatera assays using tumor and normal exome data from Personalis and take charge of commercialization. The collaboration aims to improve availability and reliability of advanced cancer diagnostics.
Personalis, Inc. (Nasdaq: PSNL) has announced participation in two upcoming investor conferences. The management team will present at the Cowen 41st Annual Healthcare Conference on March 2, 2021, at 1:30 p.m. ET, and at the Barclays Global Healthcare Conference on March 10, 2021, at 11:30 a.m. ET. Personalis specializes in advanced genomics for cancer, operating one of the largest sequencing programs and providing critical molecular data through its ImmunoID NeXT Platform.
Personalis, Inc. (Nasdaq: PSNL) announced it will release its fourth quarter 2020 financial results after the market closes on February 25, 2021. A conference call and webcast will follow at 2:00 p.m. PT / 5:00 p.m. ET to discuss these results and recent highlights. Interested parties can join via telephone or through the company's website.
FAQ
What is the current stock price of Personalis (PSNL)?
What is the market cap of Personalis (PSNL)?
What does Personalis, Inc. specialize in?
What are Personalis' main products?
Who can benefit from Personalis' services?
What technologies does Personalis use?
What is the mission of Personalis, Inc.?
How does Personalis support cancer research?
What recent achievements has Personalis made?
What sets Personalis apart from other genomic companies?
Why is genome sequencing important in medical research?
How can I stay updated on Personalis' latest news?
